MIAMI, FL—Occluding the left atrial appendage (LAA) with the next-generation Watchman FLX device (Boston Scientific) produces a low rate of stroke or systemic embolism through 2 years in patients with ...
Left atrial appendage (LAA) closure with the new-generation Watchman FLX device (Boston Scientific) provides a high rate of effective closure with few early adverse events, according to results of ...
New stroke risk reduction technology designed to advance procedural performance and safety, treat wider range of patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., July 21, 2020 ...
Boston Scietific's Watchman left atrial appendage closure (LAAC) device won FDA approval in 2015 after an unprecendented three FDA panel reviews. Since then, the Watchman device has become one of the ...
The Watchman FLX met primary safety and effectiveness endpoints in an observational study of the next-generation transcatheter left atrial appendage (LAA) closure device. Designed to improve upon the ...
MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results